A Gut Microbe and a Common Dietary Fiber Team Up to Beat Constipation

Constipation affects somewhere between 12 and 20 percent of people worldwide, and for many of them, laxatives and standard dietary advice provide only partial or temporary relief. A new study published in npj Biofilms and Microbiomes by R. Li, Q. Yang, J. He, and colleagues now points toward a more targeted approach: boosting a specific gut bacterium, Ruminococcus bromii, by feeding it resistant starch, the type of fiber found in potatoes, corn, and unripe bananas. The findings are emerging rather than definitive, but the translational arc, from patient stool samples to mouse models to a small clinical trial, makes them unusually concrete for a microbiome study.

Ruminococcus bromii identified as a key missing microbe in constipated patients

The researchers started by comparing stool samples from 20 constipated patients and 20 healthy controls using 16S rRNA sequencing. When they built a random forest model to distinguish the two groups, Ruminococcus emerged as the single highest-weight discriminative feature: the genus was significantly depleted in people with constipation. That observation set the direction for everything that followed.

All four Ruminococcus species they subsequently tested in a loperamide-induced mouse model, R. bromii, R. torques, R. obeum, and R. gnavus, reduced constipation symptoms, but R. bromii stood out. It outperformed the others across multiple physiological measures: water and sodium ion channel activity, intestinal barrier integrity, inflammatory markers, and signaling through the SCF/c-Kit pathway, which regulates the pacemaker cells that drive gut motility. R. bromii also raised levels of serotonin, indole, kynurenine, and glutamate in mouse colonic tissue, neuroactive substances that promote smooth muscle contraction and influence peristalsis.

Pullulanase enzyme drives the fiber-degradation mechanism

A genomic scan of R. bromii revealed 27 glycoside hydrolase genes, consistent with its reputation as a specialist degrader of resistant starch (RS). The team showed that RS supplementation significantly promoted R. bromii growth in lab cultures. More importantly, they generated a UV-mutated strain of the bacterium that lacked pullulanase activity, the enzyme that breaks down branched starch chains, and tested it alongside a strain engineered to overexpress pullulanase. The mutant strain lost most of its anti-constipation benefit; the overexpressing strain enhanced it. Pullulanase, in other words, is not incidental to R. bromii's effects: it is the mechanism.

When R. bromii degrades resistant starch via pullulanase, it produces short-chain fatty acids (SCFAs), particularly propionate and butyrate. Those SCFAs do several things simultaneously: they upregulate water channel proteins and epithelial sodium channels to improve fluid absorption in the colon, they stimulate mucus secretion to strengthen the gut barrier, and they appear to encourage the growth of two other beneficial species, Akkermansia muciniphila and Bifidobacterium longum. Antibiotic pretreatment in mice blunted the effect of R. bromii, confirming that the bacterium relies on an intact microbial environment to deliver its full benefit.

A small clinical trial links resistant starch to symptom relief

34 constipation patients received 10 grams of HI-MAIZE 260 resistant starch twice daily for 14 days in a non-randomized controlled trial. Constipation symptoms improved, and so did quality-of-life scores. Crucially, the magnitude of improvement correlated with the presence and increased abundance of R. bromii in fecal metagenomic samples, a finding that ties the clinical signal back to the bacterium identified at the outset. Separate randomized trial evidence has also found resistant starch type 3 relieves constipation symptoms while increasing beneficial bacteria, lending broader context to the current results.

The mechanistic picture that emerges is relatively coherent: resistant starch feeds R. bromii, which uses pullulanase to break it down into SCFAs, which in turn regulate fluid balance, barrier function, and gut motility while reshaping the surrounding microbial community. Serotonin and related neuroactive compounds add a neuromuscular layer to that picture. Notably, R. bromii also reduced anxiety- and depression-like behaviors in constipated mice, a reminder that gut-brain crosstalk extends beyond digestion.

Caveats that temper the clinical takeaway

Several limitations deserve direct acknowledgment. The clinical trial was non-randomized, which limits causal inference. 34 patients over 14 days is a short window for a condition that is often chronic. The safety profile of R. bromii as a live biotherapeutic product has not been established in formal preclinical or clinical safety studies. Perhaps most intriguingly, when the researchers combined R. bromii, Akkermansia, and Bifidobacterium in mouse models, they saw no synergistic benefit beyond what R. bromii alone produced, suggesting the interactions among these species are more complex than a simple additive story.

Those caveats align with a broader pattern: human trials of resistant starch are still limited in scale and methodological consistency, and individual variation in gut microbiota composition strongly influences how much SCFA benefit any given person gets from RS. Resistant starch is not a one-size-fits-all intervention, and the clinical value of directly supplementing R. bromii remains to be tested in a properly controlled trial.

What the pullulanase finding opens up for future research

The most actionable near-term direction suggested by this work is the combination strategy: prebiotic resistant starch to amplify R. bromii in patients who already carry the bacterium, rather than live probiotic delivery of the organism itself. Resistant starch has a long history of safe use in foods and supplements, which makes it an easier regulatory and practical path than a novel live biotherapeutic. Deeper work mapping how specific RS types interact with specific microbial species will be needed to design more precise dietary protocols and understand which patients are most likely to respond.

For now, the study adds a mechanistically grounded candidate, pullulanase-driven starch fermentation by R. bromii, to a field that has long struggled to move beyond symptom management toward root-cause intervention. Whether that candidate survives larger, randomized trials is the question that needs answering next.

Evidence rating

EMERGING — 78/100

Caveats:

• The clinical component was a non-randomized trial with only 34 patients and no control group, meaning causation cannot be firmly established and results may not generalize broadly.
• Most mechanistic data come from a loperamide-induced mouse model, which does not fully replicate human functional constipation.
• Funding source was not disclosed by the authors, limiting full assessment of potential conflicts of interest.
• R. bromii as a live biotherapeutic has not yet been validated for safety in humans through formal clinical trials.
• No synergistic benefit was observed when R. bromii was combined with Akkermansia and Bifidobacterium in mice, leaving combination therapy strategies unresolved.

This translational study combined 16S rRNA sequencing of 40 human stool samples (20 constipated, 20 healthy controls), multiple loperamide-induced mouse model experiments, and a non-randomized clinical trial in 34 constipated patients receiving resistant starch for 14 days. The mouse work establishes a detailed mechanistic chain linking R. bromii pullulanase activity to SCFA production and gut motility, but the clinical component lacks a control arm, limiting causal inference in humans. The findings are internally consistent and mechanistically specific, though independent replication in a larger, randomized human trial has not yet been conducted.